Erratum to: T-Cell Trafficking and Anti-Adhesion Strategies in Inflammatory Bowel Disease: Current and Future Prospects (Drugs (2014) DOI :10.1007/s40265-013-0176-2);T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: Current and future prospects

Drugs

Volumn 74, Issue 3, 2014, Pages 297-311

  Mosli, Mahmoud H ^a,b,c   Rivera Nieves, Jesus ^d   Feagan, Brian G ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AJM 300; ALICAFORSEN; ALPHA4 INTEGRIN; BETA7 INTEGRIN; C REACTIVE PROTEIN; CHOLERA VACCINE; EFALIZUMAB; ELDELUMAB; ETROLIZUMAB; FINGOLIMOD; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GSK 1607586; HEPATITIS B VACCINE; INTERCELLULAR ADHESION MOLECULE 1; INXC; ISIS 2303; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MESSENGER RNA; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PF 547659; RG 7413; RPC 1063; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VEDOLIZUMAB; VERCIRNON; VERY LATE ACTIVATION ANTIGEN 4; BETA INTEGRIN; INTEGRIN; INTEGRIN ALPHA4BETA7;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; CELLULAR IMMUNITY; CLINICAL PRACTICE; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INTERNALIZATION; LEUKOCYTE ADHERENCE; LEUKOCYTE ROLLING; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; MAINTENANCE THERAPY; MOLECULAR BIOLOGY; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN PHOSPHORYLATION; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REMISSION; REVIEW; SEROLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT RESPONSE; ULCERATIVE COLITIS; AGONISTS; ANTAGONISTS AND INHIBITORS; CELL ADHESION; CELL MOTION; CHEMICALLY INDUCED; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; PHYSIOLOGY;

CELL ADHESION; CELL MOVEMENT; CHEMOKINE CXCL10; HUMANS; INFLAMMATORY BOWEL DISEASES; INTEGRIN ALPHA4; INTEGRIN BETA CHAINS; INTEGRINS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84895827127     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0192-x     Document Type: Erratum

References (90)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066-78.
2. Kucharzik T, Maaser C, Lugering A, Kagnoff M, Mayer L, Targan S, et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis. 2006;12(11):1068-83.
3. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427-34.
4. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641-57 (*A comprehensive review of recently developed therapies for IBD).
5. Cottone M, Renna S, Orlando A, Mocciaro F. Medical management of Crohn's disease. Expert Opin Pharmacother. 2011;12(16):2505-25.
6. Cohen RD. Evolving medical therapies for ulcerative colitis. Current Gastroenterol Rep. 2002;4(6):497-505.
7. Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. Immunity. 2013;38(3):414-23.
8. Hogan SP, Waddell A, Fulkerson PC. Eosinophils in infection and intestinal immunity. Current Opin Gastroenterol. 2013;29(1):7-14.
9. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nature Rev Immunol. 2011;11(8):519-31.
10. Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H. The role of the T cell in autoimmune inflammation. Arthritis Res Therapy. 2005;7(Suppl 2):S4-14.
11. McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. Immunity. 2008;28(4):445-53.
12. Troncone E, Marafini I, Pallone F, Monteleone G. Th17 cytokines in inflammatory bowel diseases: discerning the good from the bad. Int Rev Immunol. 2013;32(5-6):526-33.
13. Boden EK, Snapper SB. Regulatory T cells in inflammatory bowel disease. Current Opin Gastroenterol. 2008;24(6):733-41.
14. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006;212:256-71.
15. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol. 2003;171(11):6164-72.
16. Salmi M, Jalkanen S. Cell-surface enzymes in control of leukocyte trafficking. Nature Rev Immunol. 2005;5(10):760-71.
17. Panes J, Granger DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology. 1998;114(5):1066-90.
18. Mora JR, von Andrian UH. T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol. 2006;27(5):235-43.
19. Bargatze RF, Jutila MA, Butcher EC. Distinct roles of l-selectin and integrins alpha 4 beta 7 and LFA-1 in lymphocyte homing to Peyer's patch-HEV in situ: the multistep model confirmed and refined. Immunity. 1995;3(1):99-108.
20. Brownlie RJ, Zamoyska R. T cell receptor signalling networks: branched, diversified and bounded. Nature Rev Immunol. 2013;13(4):257-69.
21. Schmidt S, Moser M, Sperandio M. The molecular basis of leukocyte recruitment and its deficiencies. Mol Immunol. 2013;55(1):49-58.
22. Sundd P, Pospieszalska MK, Cheung LS, Konstantopoulos K, Ley K. Biomechanics of leukocyte rolling. Biorheology. 2011;48(1):1-35.
23. Hunt SW 3rd, Harris ES, Kellermann SA, Shimizu Y. T-lymphocyte interactions with endothelium and extracellular matrix. Crit Rev Oral Biol Med Off Publ Am Assoc Oral Biol. 1996;7(1):59-86.
24. Rao RM, Shaw SK, Kim M, Luscinskas FW. Emerging topics in the regulation of leukocyte transendothelial migration. Microcirculation. 2005;12(1):83-9.
25. Takuwa Y, Okamoto Y, Yoshioka K, Takuwa N. Sphingosine-1-phosphate signaling in physiology and diseases. Biofactors. 2012;38(5):329-37.
26. Edmonds Y, Milstien S, Spiegel S. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling. Pharmacol Ther. 2011;132(3):352-60.
27. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. The Journal of pharmacology and experimental therapeutics. 2009;330(3):864-75 (* *This article is a very useful reference to help understand the pharmacological aspects of vedolizumab action).
28. Hesterberg PE, Winsor-Hines D, Briskin MJ, Soler-Ferran D, Merrill C, Mackay CR, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996;111(5):1373-80.
29. Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology. 2012;20(1):1-18.
30. von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003;348(1):68-72.
31. Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007;68(16):1299-304.
32. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15-23.
33. O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. 2004;62(11):2038-43.
34. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
35. Berger JR. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Safety Int J Med Toxicol Drug Exp. 2010;33(11):969-83.
36. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353(4):362-8.
37. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348(1):24-32.
38. Gordon FH, Hamilton MI, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther. 2002;16(4):699-705.
39. Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology. 2001;121(2):268-74.
40. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353(18):1912-25.
41. Feagan BG, McDonald JW, Rochon J, Laupacis A, Fedorak RN, Kinnear D, et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med. 1994;330(26):1846-51.
42. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007;132(5):1672-83 (* *An important study for readers to review regarding the efficacy of natalizumab).
43. Tysabri. The TYSABRI TOUCH® Prescribing Program. 2013 [cited 2013 Septmeber 29]. http://www.tysabri.com/safety-with-tysabri.xml.
44. Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology. 2012;78(22):1736-42.
45. Pinto M, Dobson S. BK and JC virus: a review. J Infect. 2013;68 Suppl 1: S2-8.
46. Comar M, Delbue S, Lepore L, Martelossi S, Radillo O, Ronfani L, et al. Latent viral infections in young patients with inflammatory diseases treated with biological agents: prevalence of JC virus genotype 2. J Med Virol. 2013;85(4):716-22.
47. Kleinschmidt-Demasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol. 2012;71(7):604-17.
48. Kane SV, Horst S, Sandborn WJ, Becker B, Neis B, Moscandrew M, et al. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis. 2012;18(12):2203-8.
49. Takazoe M, Watanabe M, Kawaguchi T, Matsumoto T, Oshitani N, Hiwatashi N, Hibi T. Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease - a randomized, double-blind, placebo-controlled trial. DDW, AGA. 2009;S1066.
50. Feagan BG, McDonald J, Greenberg GR, Wild G, Pare P, Fedorak R, Landau SB, Brettman LR. An ascending dose trial of humanized A4B7 antibody in ulcerative colitis. Gastroenterology. 2000; 118(4 suppl 2): A874.
51. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352(24):2499-507 (* *The first study to examine the effects of inhibiting alpha4beta7 as a therapeutic target for inflammatory bowel disease. Epub 2005/06/17.This is an important clinical trial that illustrated the efficacy of vedolizumab in the treatment of UC).
52. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2008;6(12):1370-7 (* *A pivotal phase-II study. Epub 2008/10/03).
53. Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflammatory bowel diseases. 2011;18(8):1470-9 (* *An important phase-IIb study that provided significant insight into the pharmacological profile of vedolizumab. Epub 2011/12/08).
54. Parikh A, Fox I, Leach T, Xu J, Scholz C, Patella M, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(8):1691-9
55. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710.
56. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-21.
57. Sands BE, Feagan BG, Rutgeerts P, Colombel J-F, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S. Vedolizumab induction therapy for patients with Crohn's disease who failed tumor necrosis factor antagonist treatment. 2013 (In Press).
58. Feagan B. Long-term safety of vedolizumab for the treatment of ulcerative colitis or Crohn's disease. United Eur Gastroenterol Week (UEGW). 2013.
59. Cepek KL, Parker CM, Madara JL, Brenner MB. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol. 1993;150(8 Pt 1):3459-70.
60. Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B, et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut. 2013;62(8):1122-30
61. Vermeire S, Ghosh S, Panes J, Dahlerup JF, Luegering A, Sirotiakova J, et al. The mucosal address in cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut. 2011;60(8):1068-75.
62. Philpott JR, Miner PB Jr. Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD. Expert Opin Biol Ther. 2008;8(10):1627-32.
63. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology. 1998;114(6):1133-42.
64. Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology. 2001;120(6):1339-46.
65. Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther. 2002;16(10):1761-70.
66. Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut. 2002;51(1):30-6.
67. van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2006;23(10):1415-25.
68. Miner PB Jr, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther. 2006;23(10):1403-13.
69. Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther. 2004;19(3):281-6.
70. Simmons DL. Anti-adhesion therapies. Curr Opin Pharmacol. 2005;5(4):398-404.
71. Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M. Dal Pan G. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol. 2011;65(3):546-51.
72. Eksteen B, Adams DH. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs Invest Drugs J. 2010;13(7):472-781.
73. ChemoCentryx. CCR9 Program. http://www.chemocentryx.com/product/CCR9. html: ChemoCentryx; 2012 (cited 2012 1/7/2012).
74. Release CP. ChemoCentryx announces GlaxoSmithKline's release of top-line results from the SHIELD-1 Phase III study of vercirnon. 2013. http://ir.chemocentryx.com/releasedetail.cfm?ReleaseID=786941August; http://ir.chemocentryx.com/releasedetail.cfm?ReleaseID=786941.
75. Feagan BG, Sandborn W, D'Haens G, Lee SD, Allez M, Fedorak R, Seidler U, Vermeire S, Lawrance I, Jurgensen CH, Heath A, Chang DJ, For the SHIELD-1 Investigators. Vercirnon, an Oral CCR9 antagonist, as induction therapy in active Crohn's disease: randomized, double-blind, placebo-controlled, Phase 3 Trial. San Deigo: ACG; 2013.
76. Wermers JD, McNamee EN, Wurbel MA, Jedlicka P, Rivera-Nieves J. The chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice. Gastroenterology. 2011;140(5):1526-5 e3 (Epub 2011/02/09).
77. Wurbel MA, McIntire MG, Dwyer P, Fiebiger E. CCL25/CCR9 interactions regulate large intestinal inflammation in a murine model of acute colitis. PloS one. 2011;6(1):e16442 (Epub 2011/02/02).
78. Rojas-Lopez AE, Soldevila G, Meza-Perez S, Dupont G, Ostoa-Saloma P, Wurbel MA, et al. CCR9 + T cells contribute to the resolution of the inflammatory response in a mouse model of intestinal amoebiasis. Immunobiology. 2012;217(8):795-807.
79. Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2013 (Epub 5 Mar).
80. ClinicalTrials.gov. A Phase IIa, double-blind, randomized, placebo-controlled study to evaluate the clinical efficacy and safety of induction and maintenance therapy with BMS-936557 in subjects with active Crohn's disease. 2013 (cited 2013 June, 11). http://clinicaltrials.gov/ct2/show/ NCT01466374?term=BMS-936557&rank=1.
81. ClinicalTrials.gov. A Phase IIb randomized, placebo-controlled study to evaluate the clinical efficacy and safety of induction and maintenance therapy with BMS-936557 in subjects with active ulcerative colitis (UC). 2013 (cited 2013 June, 11). http://clinicaltrials.gov/ct2/show/NCT01294410?term=BMS- 936557&rank=2.
82. Melzer N, Meuth SG. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies. Clin Exp Immunol. 2013 (Epub 27 Aug).
83. Receptos. SPHINGOSINE-1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS. Receptos.com2012 (cited 2012 October 29). http://www.receptos.com/clinical- pipeline-at-receptos.php.
84. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-80.
85. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010;61:35-47.
86. Erle DJ, Briskin MJ, Butcher EC, Garcia-Pardo A, Lazarovits AI, Tidswell M. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J Immunol. 1994;153(2):517-28.
87. Parikh A FE, Soler D, Wyant T, Kadambi V, Leach T, Milch C, Fox I, (Millennium: The Takeda Oncology Company C, MA, US). Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to the alpha4beta7 integrin. CCF; Florida: Inflammatory Bowel Disease; 2008. p. S18 P-0025 (* *An important study that highlights the gut selective properties of vedolizumab).
88. Leclerc M, Lesesve JF, Gaillard B, Troussard X, Tourbah A, Debouverie M, et al. Binucleated lymphocytes in patients with multiple sclerosis treated with natalizumab. Leukemia Lymphoma. 2011;52(5):910-2.
89. Wyant TL, Sankoh S, Wang Y, Paolino J, Pasetti MF, Feagan BG, Parikh A. A phase 1, double-blind placebo-controlled single-dose study to determine the immune response to systemic and mucosal antigenic challenge in the presence of vedolizumab. ECCO. 2013;592 (abstract).
90. Rivera-Nieves J, Gorfu G, Ley K. Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(12):1715-35.